• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Praxis Precision Medicines, Inc. - Common Stock (NQ:PRAX)

    283.23 -51.93 (-15.49%)
    Streaming Delayed Price Updated: 12:57 PM EDT, Jun 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 754,963
    Open 307.01
    Bid (Size) 283.19 (40)
    Ask (Size) 284.56 (160)
    Prev. Close 335.16
    Today's Range 281.28 - 321.75
    52wk Range 37.19 - 366.52
    Shares Outstanding 44,712,538
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Praxis Precision Medicines Provides Vormatrigine Program Update
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter ↗
    This clinical-stage biotech develops precision genetic medicines for neurological and hepatic disorders via its PRISM platform. 
    Via The Motley Fool
    Topics Regulatory Compliance

    Performance

    YTD
    -1.1%
    -1.1%
    1 Month
    -16.1%
    -16.1%
    3 Month
    -14.3%
    -14.3%
    6 Month
    +53.5%
    +53.5%
    1 Year
    +611.3%
    +611.3%

    More News

    Read More
    News headline image
    Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    Praxis Precision Medicines (NASDAQ:PRAX) Beats Q1 Estimates as FDA Accepts Two Key Drug Applications ↗
    Via Chartmill
    News headline image
    Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1 ↗
    Via The Motley Fool
    Topics Regulatory Compliance Stocks
    News headline image
    Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline ↗
    Via The Motley Fool
    Topics Intellectual Property Regulatory Compliance
    News headline image
    Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year ↗
    Via The Motley Fool
    Topics Economy Regulatory Compliance
    News headline image
    Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares ↗
    Via The Motley Fool
    News headline image
    Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally ↗
    Via The Motley Fool
    News headline image
    Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Praxis (PRAX) Q1 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Praxis Precision Medicines Q1 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Praxis Precision Medicines, Inc. - Common Stock publicly traded?
    Yes, Praxis Precision Medicines, Inc. - Common Stock is publicly traded.
    What exchange does Praxis Precision Medicines, Inc. - Common Stock trade on?
    Praxis Precision Medicines, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Praxis Precision Medicines, Inc. - Common Stock?
    The ticker symbol for Praxis Precision Medicines, Inc. - Common Stock is PRAX on the Nasdaq Stock Market
    What is the current price of Praxis Precision Medicines, Inc. - Common Stock?
    The current price of Praxis Precision Medicines, Inc. - Common Stock is 283.23
    When was Praxis Precision Medicines, Inc. - Common Stock last traded?
    The last trade of Praxis Precision Medicines, Inc. - Common Stock was at 06/02/26 12:57 PM ET
    What is the market capitalization of Praxis Precision Medicines, Inc. - Common Stock?
    The market capitalization of Praxis Precision Medicines, Inc. - Common Stock is 12.66B
    How many shares of Praxis Precision Medicines, Inc. - Common Stock are outstanding?
    Praxis Precision Medicines, Inc. - Common Stock has 13B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.